Media Center

Blog Posts

Oct 01, 2026

Engineering CAR T-Cells to Function Where Others Fail

Aug 07, 2026

Designing Beyond Tolerability Limits: Advancing GB-4362 Into Clinical Development

Media Highlights

Oct 15, 2026

Media Highlights

Zealand Pharma CEO hails AI protein deal with Generate Biomedicines

View on MedWatch

Oct 13, 2026

Media Highlights

Zealand Pharma Makes Deal With Generate Worth Up to $1.2 Billion

View on Bloomberg

News Releases

Oct 13, 2026

Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Oct 01, 2026

Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer

Presentations & Publications

Sep 08, 2026

Presentations & Publications

GB-0895 SOLAIRIA-1 & SOLAIRIA-2 ERS Barcelona 2026 Final